Neurology Section, Movement Disorders Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2350, 90035-00 Porto Alegre, RS, Brazil.
J Biotechnol. 2011 Mar 20;152(3):96-101. doi: 10.1016/j.jbiotec.2011.01.023. Epub 2011 Feb 3.
The present study demonstrates that blood samples can be used as a source of miRNA identification associated to Parkinson's disease (PD). A set of six differentially expressed microRNAs were identified. They form two groups according to their expression profile in control, non-treated, early-onset and treated Parkinson's disease subjects. While miR-1, miR-22* and miR-29 expression levels allowed to distinguish non-treated PD from healthy subjects, miR-16-2*, miR-26a2* and miR30a differentiated treated from untreated patients. This study is innovative in contributing to the development of effective PD biomarkers.
本研究表明，血液样本可用作与帕金森病（PD）相关的 miRNA 鉴定的来源。鉴定出了一组 6 个差异表达的 microRNA。根据它们在对照、未经治疗、早发性和治疗性帕金森病受试者中的表达谱，它们分为两组。虽然 miR-1、miR-22* 和 miR-29 的表达水平可将未经治疗的 PD 与健康受试者区分开来，但 miR-16-2*、miR-26a2* 和 miR30a 则可将治疗组与未治疗组区分开来。这项研究的创新性在于为开发有效的 PD 生物标志物做出了贡献。
